Therapeutic strategies for diseases caused by loss-of-function mutations in G protein-coupled receptors

被引:5
作者
Wang, Wei [1 ]
Guo, Dong-Yu [1 ]
Tao, Ya-Xiong [2 ]
机构
[1] Xiamen Huli Guoyu Clin Co Ltd, Dept Clin Lab, Xiamen, Fujian, Peoples R China
[2] Auburn Univ, Coll Vet Med, Dept Anat Physiol & Pharmacol, Auburn, AL 36849 USA
来源
G PROTEIN SIGNALING PATHWAYS IN HEALTH AND DISEASE | 2019年 / 161卷
关键词
NEPHROGENIC DIABETES-INSIPIDUS; VASOPRESSIN V2 RECEPTOR; CELL-SURFACE EXPRESSION; LUTEINIZING-HORMONE-RECEPTOR; MOLECULAR-WEIGHT AGONIST; PROOPIOMELANOCORTIN-DERIVED AGONISTS; PREVENTS RETINAL DEGENERATION; MELANOCORTIN; RECEPTOR; PHARMACOLOGICAL CHAPERONES; NONSENSE MUTATIONS;
D O I
10.1016/bs.pmbts.2018.09.002
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
As one of the largest families of cell membrane proteins, G protein-coupled receptors (GPCRs) are involved in regulating almost all physiological processes by transducing extracellular signals into the cytoplasm. Since the first discovery of naturally occurring mutations in Rhodopsin gene in 1990, hundreds of loss-of-function mutations in multiple GPCRs have been identified to be pathogenic for more than 30 diverse human diseases, making these defective receptors important drug targets for personalized medicine. In this review, we aim to elucidate the etiologies of five common inherited diseases caused by six of the most extensively studied GPCRs. The molecular basis and classification of inactivating mutations in GPCRs are also reviewed. The available therapeutic approaches directed against different classes of mutants, especially pharmacological chaperones targeting intracellularly retained mutants, reported during the past two decades, are systematically summarized.
引用
收藏
页码:181 / 210
页数:30
相关论文
共 50 条
[11]   G protein-coupled receptors and the regulation of autophagy [J].
Wauson, Eric M. ;
Dbouk, Hashem A. ;
Ghosh, Anwesha B. ;
Cobb, Melanie H. .
TRENDS IN ENDOCRINOLOGY AND METABOLISM, 2014, 25 (05) :274-282
[12]   Modulation of proteostasis and protein trafficking: a therapeutic avenue for misfolded G protein-coupled receptors causing disease in humans [J].
Ulloa-Aguirre, Alfredo ;
Janovick, Jo Ann .
EMERGING TOPICS IN LIFE SCIENCES, 2019, 3 (01) :39-52
[13]   The nature of efficacy at G protein-coupled receptors [J].
Zhao, Peishen ;
Furness, Sebastian G. B. .
BIOCHEMICAL PHARMACOLOGY, 2019, 170
[14]   G Protein-Coupled Receptors as Regulators of Glucose Homeostasis and Therapeutic Targets for Diabetes Mellitus [J].
Tao, Ya-Xiong ;
Liang, Xu-Fang .
GLUCOSE HOMEOSTATIS AND THE PATHOGENESIS OF DIABETES MELLITUS, 2014, 121 :1-21
[15]   Towards the convergent therapeutic potential of G protein-coupled receptors in autism spectrum disorders [J].
Annamneedi, Anil ;
Gora, Caroline ;
Dudas, Ana ;
Leray, Xavier ;
Bozon, Veronique ;
Crepieux, Pascale ;
Pellissier, Lucie P. .
BRITISH JOURNAL OF PHARMACOLOGY, 2025, 182 (14) :3044-3067
[16]   Enhancement of the surface expression of G protein-coupled receptors [J].
Dunham, Jill H. ;
Hall, Randy A. .
TRENDS IN BIOTECHNOLOGY, 2009, 27 (09) :541-545
[17]   Presynaptic G Protein-Coupled Receptors: Gatekeepers of Addiction? [J].
Johnson, Kari A. ;
Lovinger, David M. .
FRONTIERS IN CELLULAR NEUROSCIENCE, 2016, 10
[18]   Nonpeptide Ligands for Peptidergic G Protein-Coupled Receptors [J].
Geary, Timothy G. .
NEUROPEPTIDE SYSTEMS AS TARGETS FOR PARASITE AND PEST CONTROL, 2010, 692 :10-26
[19]   Chaperoning G Protein-Coupled Receptors: From Cell Biology to Therapeutics [J].
Tao, Ya-Xiong ;
Conn, P. Michael .
ENDOCRINE REVIEWS, 2014, 35 (04) :602-647
[20]   Engineering G Protein-Coupled Receptors for Drug Design [J].
Congreve, Miles ;
Dore, Andrew S. ;
Jazayeri, Ali ;
Nonoo, Rebecca .
MULTIFACETED ROLES OF CRYSTALLOGRAPHY IN MODERN DRUG DISCOVERY, 2015, :1-18